Jazz Pharmaceuticals plc (JAZZ) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $202.22 — A.R:R 0.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: oxybate revenues.
Jazz Pharmaceuticals is a global biopharmaceutical company focused on rare diseases including epilepsies, cancers, and sleep disorders, with marketed products including Xywav, Epidiolex, Ziihera, Zepzelca, and Rylaze. Revenue is derived from specialty pharmaceutical sales... Read more
Sell if holding. Analyst target reached at $202.22 — A.R:R 0.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: oxybate revenues. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 4/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductoxybate revenues10-K Item 1A: 'our business will continue to be meaningfully dependent on oxybate revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $202.22 — A.R:R 0.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: oxybate revenues. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $191.66. Score 5.4/10, moderate confidence.
Take-profit target: $202.98 (+0.4% upside). Prior stop was $191.66. Stop-loss: $191.66.
Concentration risk — Product: oxybate revenues; Analyst target reached - limited upside remaining; Near 52-week high (2.5% away).
Jazz Pharmaceuticals plc trades at a P/E of N/A (forward 7.9). TrendMatrix value score: 7.7/10. Verdict: Sell.
23 analysts cover JAZZ with a consensus score of 4.3/5. Average price target: $226.
What does Jazz Pharmaceuticals plc do?Jazz Pharmaceuticals is a global biopharmaceutical company focused on rare diseases including epilepsies, cancers, and...
Jazz Pharmaceuticals is a global biopharmaceutical company focused on rare diseases including epilepsies, cancers, and sleep disorders, with marketed products including Xywav, Epidiolex, Ziihera, Zepzelca, and Rylaze. Revenue is derived from specialty pharmaceutical sales primarily in the US, concentrated in rare disease markets with small patient populations and efficient call points.